Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 119.22 billion. The enterprise value is 114.87 billion.
Market Cap | 119.22B |
Enterprise Value | 114.87B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | Sep 17, 2024 |
Share Statistics
Marksans Pharma has 453.16 million shares outstanding. The number of shares has increased by 6.46% in one year.
Shares Outstanding | 453.16M |
Shares Change (YoY) | +6.46% |
Shares Change (QoQ) | +0.06% |
Owned by Insiders (%) | 43.87% |
Owned by Institutions (%) | 10.57% |
Float | 204.31M |
Valuation Ratios
The trailing PE ratio is 35.75 and the forward PE ratio is 30.83. Marksans Pharma's PEG ratio is 1.28.
PE Ratio | 35.75 |
Forward PE | 30.83 |
PS Ratio | 5.26 |
PB Ratio | 5.77 |
P/FCF Ratio | n/a |
PEG Ratio | 1.28 |
Enterprise Valuation
EV / Earnings | 34.41 |
EV / Sales | 5.06 |
EV / EBITDA | 23.51 |
EV / EBIT | 28.43 |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 11.70 |
Debt / EBITDA | 0.50 |
Debt / FCF | n/a |
Interest Coverage | 32.19 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | 11.97% |
Revenue Per Employee | 19.88M |
Profits Per Employee | 2.93M |
Employee Count | 1,141 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +143.38% in the last 52 weeks. The beta is 1.63, so Marksans Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.63 |
52-Week Price Change | +143.38% |
50-Day Moving Average | 204.45 |
200-Day Moving Average | 169.39 |
Relative Strength Index (RSI) | 75.89 |
Average Volume (20 Days) | 4,797,486 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 22.68 billion and earned 3.34 billion in profits. Earnings per share was 7.36.
Revenue | 22.68B |
Gross Profit | 12.11B |
Operating Income | 4.04B |
Pretax Income | 4.47B |
Net Income | 3.34B |
EBITDA | 4.89B |
EBIT | 4.04B |
Earnings Per Share (EPS) | 7.36 |
Balance Sheet
The company has 7.01 billion in cash and 2.44 billion in debt, giving a net cash position of 4.57 billion or 10.07 per share.
Cash & Cash Equivalents | 7.01B |
Total Debt | 2.44B |
Net Cash | 4.57B |
Net Cash Per Share | 10.07 |
Equity (Book Value) | 20.86B |
Book Value Per Share | 45.63 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 53.39%, with operating and profit margins of 17.81% and 14.72%.
Gross Margin | 53.39% |
Operating Margin | 17.81% |
Pretax Margin | 19.70% |
Profit Margin | 14.72% |
EBITDA Margin | 21.55% |
EBIT Margin | 17.81% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.23%.
Dividend Per Share | 0.60 |
Dividend Yield | 0.23% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -6.46% |
Shareholder Yield | -6.23% |
Earnings Yield | 2.80% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |